A detailed picture of what happens when DNA transcription is paused early in the process has been obtained by structural ...

The mRNA Therapeutics market is expanding due to advancements in drug development, personalized medicine, and delivery technologies. Opportunities arise from the technology's success in vaccines and ...

NIH director Jay Bhattacharya has offered a new explanation for why the federal government canceled $500 million in contracts ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

HHS Secretary Robert F. Kennedy Jr. used discredited and misrepresented studies to justify canceling research into ...

Known as promoter-proximal pausing, this interruption in the transcription activity of RNA polymerase II—the enzyme ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents ...

The future of mRNA cancer immunotherapies is uncertain after Health and Human Services Secretary Robert F. Kennedy Jr. defunded 22 mRNA vaccine projects for flu and COVID-19.

Kennedy’s $500M cut to mRNA funding puts startups at risk and imperils one of life sciences’ few leasing bright spots.

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...